Zobrazeno 1 - 10
of 905
pro vyhledávání: '"MICHAEL J. THORPY"'
Publikováno v:
Neurology and Therapy, Vol 13, Iss 3, Pp 785-807 (2024)
Abstract Introduction Low-sodium oxybate (LXB) is approved for treatment of narcolepsy in patients aged 7 years and older and treatment of idiopathic hypersomnia in adults. LXB contains the same active moiety with 92% less sodium than sodium oxybate
Externí odkaz:
https://doaj.org/article/ddb4de20e42d43b5b8a3cec067e1dc6e
Autor:
Michael J. Thorpy, Clete A. Kushida, Richard Bogan, John Winkelman, Maurice M. Ohayon, Colin M. Shapiro, Jennifer Gudeman
Publikováno v:
Sleep Medicine: X, Vol 7, Iss , Pp 100113- (2024)
Background: In the REST-ON clinical trial (NCT02720744), mean sleep latency on the Maintenance of Wakefulness Test (MWT) was significantly improved with extended-release once-nightly sodium oxybate (ON-SXB) vs placebo (P 10 % remained awake for the e
Externí odkaz:
https://doaj.org/article/153529cfb88d475a89cba73df629c87f
Autor:
Michael J. Thorpy, Clete A. Kushida, Richard Bogan, Akinyemi O. Ajayi, Bruce C. Corser, Jennifer Gudeman
Publikováno v:
Sleep Medicine: X, Vol 7, Iss , Pp 100109- (2024)
Background: Once-nightly sodium oxybate (ON-SXB), an extended-release oxybate formulation, yielded significant (P
Externí odkaz:
https://doaj.org/article/b54aaf543f4a43fc965fc4eb50c20c54
Autor:
Flavio S. Aloe, Michael J. Thorpy
Publikováno v:
Arquivos de Neuro-Psiquiatria, Vol 53, Iss 1, Pp 46-52 (1995)
Seven patients (mean age 46.6; range 33-58; 6M.1F) presented with sleep-related choking episodes and were found to have features in common that distinguished them from other known causes of choking episodes during sleep. The characteristic features i
Externí odkaz:
https://doaj.org/article/002cb2bf8ea24267b2d19fb45749e433
This up-to-date, superbly illustrated book is a practical guide to the effective use of neuroimaging in the patient with sleep disorders. There are detailed reviews of new neuroimaging techniques – including CT, MRI, advanced MR techniques, SPECT a
Publikováno v:
CNS Drugs. 37:323-335
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fd9b59ba8dd40615ef125e9d1475f3a0
https://doi.org/10.1007/s40263-023-00992-y
https://doi.org/10.1007/s40263-023-00992-y
Autor:
Haramandeep Singh, Danielle Hyman, Gregory S. Parks, Abby Chen, Catherine Foley, Beth Baldys, Diane Ito, Michael J. Thorpy
Publikováno v:
Advances in Therapy. 39:4359-4373
Solriamfetol (Sunosi™), a dopamine/norepinephrine reuptake inhibitor, is approved (USA and EU) to treat excessive daytime sleepiness (EDS) in adults with obstructive sleep apnea (OSA) (37.5-150 mg/day). Real-world research on solriamfetol initiatio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e62759cea58878c70e48169298c8e04e
https://doi.org/10.1007/s12325-022-02249-4
https://doi.org/10.1007/s12325-022-02249-4
Autor:
Yves Dauvilliers, Thomas Roth, Richard Bogan, Michael J Thorpy, Anne Marie Morse, Asim Roy, Jordan Dubow, Jennifer Gudeman
Publikováno v:
SLEEP.
Study Objectives Post hoc analyses from the phase 3 REST-ON trial evaluated efficacy of extended-release once-nightly sodium oxybate (ON-SXB; FT218) vs placebo for daytime sleepiness and disrupted nighttime sleep in narcolepsy type 1 (NT1) and 2 (NT2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e7c6b43bfeda2dd98692488511dbd566
https://doi.org/10.1093/sleep/zsad152
https://doi.org/10.1093/sleep/zsad152
Autor:
Anne Marie Morse, Lois Krahn, Julie Flygare, Clete Kushida, Michael J. Thorpy, Amod Athavale, Jennifer Gudeman
Publikováno v:
Advances in Therapy.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::75e41c56e5a8e1e585c3cb74cef3781d
https://doi.org/10.1007/s12325-023-02532-y
https://doi.org/10.1007/s12325-023-02532-y
Autor:
Yves Dauvilliers, Karel Šonka, Richard K. Bogan, Markku Partinen, Rafael Del Rio Villegas, Nancy Foldvary-Schaefer, Roman Skowronski, Abby Chen, Jed Black, Franck Skobieranda, Michael J. Thorpy
Publikováno v:
CNS Drugs. 36:633-647
Lower-sodium oxybate (LXB) is an oxybate medication with the same active moiety as sodium oxybate (SXB) and a unique composition of cations, resulting in 92% less sodium. LXB was shown to improve cataplexy and excessive daytime sleepiness in people w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::46ade97f24ec41c8d56c67e1e6552e70
https://doi.org/10.1007/s40263-022-00926-0
https://doi.org/10.1007/s40263-022-00926-0